The Highwire with Del Bigtree - FDA PUSHES FAILING VACCINES ON CHILDREN

Episode Date: May 22, 2022

FDA PUSHES FAILING VACCINES ON CHILDRENBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.

We're looking at Peter Marks. He was recently in a closed-door session. He's the head of the FDA at this point. He's the acting director. He was in a closed-door session with Representative Jim Clyburn. Jim Clyburn's the chairman of the select subcommittee on the coronavirus crisis. That's the official title of this. And Representative Clyburn issued a statement after that briefing with Peter Marks. And he had these quotes to say in here. Here's the actual briefing document. And he said this, FDA will not withhold authorization. based exclusively on vaccine efficacy at preventing symptomatic infection. He says Dr. Marks explained that FDA would not withhold authorization for a pediatric vaccine solely because it did not reach a 50% efficacy threshold at blocking symptomatic infection, a requirement that had been previously listed in FDA guidance. So we're skipping that apparently. He goes on to say, Dr. Marks confirmed, quote, if these vaccines seem to be mirroring efficacy in adults and just seem to be less effective

against Omicron like they are for adults, we will probably still authorize. And these are extremely sweeping statements. You've got to wonder if they did this behind closed doors because those sound bites would be really damning at this point. Not good. I mean, because everyone's looking at it. Everyone is catching Amacron. Even Tony Fauci said the vaccine is absolutely useless.

So, I mean, here you have where you're ignoring the known side effects. You're having to make ads for all the kids that are dropping over on the soccer field, clutching their chests. And while you're putting them at that risk, we don't even care if the thing is totally ineffective. we're going to still approve it for them and recommend it to them. And let's look, is this a risk category? These kids, are they at high risk?

You know, we've covered this before, but if they're going to keep pushing it like this, we have to keep pushing back with the data here. So let's look at the CDC's own MMWR report. This is like their in-house science journal. Yeah. This is the serial prevalence of infection-induced SARS-CoV two antibodies in the United States from December 2021 to February 2020.

And serop prevalence is just the amount of infection in the population as tested by the antibodies. Now, it says during December 2021 to February 2022, overall U.S. serial prevalence increased from 33.5% to 57.7%. That's everybody. Now, let's look at the kids. People can see this is sort of the herd immunity number, those that have been infected that are now carrying antibodies.

Okay. Yeah, absolutely. And then it says here, over the same period, serial prevalence increased from 44.2% to 75.2% among, children age 0 to 11 and from 45.6% to 74.2% among persons age 12 to 17. So basically 75% of kids are now testing positive for having been previously infected. You've watched what Geert Van Bosch has said. Those are your vacuum cleaners. Those are the ones that are going to create such a brilliant immunity. They're the only ones that can neutralize it. They're at 75%. That has hurt

immunity folks. Every way sideways, natural immunity amongst your kids. If it was just a world kids, we would just be fine, but it's not. But still, they want to vaccinate those kids and erase that incredible amount of immunity. All right. Continue on. And a side note, those kids from zero to 17 have never had a Moderna shot in their arm. Why is that important? We're going to talk about it in just a second. So keep that as a note. So let's look at the American Academy of Pediatrics. They keep data as well on state reporting, 46 states reporting COVID mortality, cases, hospitalizations. This is their update on May 5th. So this is This is from the start of the pandemic, start of the recording to May 5th, the entire time here.

This is what they have to say. Cumulative mortality, 46 states reporting. Among states reporting children were 0.00% to 0.27% of all COVID-19 deaths and three states reported zero child deaths. And here's the kicker. In states reporting, 0% to 0.02% of all child COVID-19 cases resulted in death. I don't know what to say about that. I mean, where are we at... The case fatality rate is at the very highest 0.02% for a child that catches this.

And in most times, it's just 0.00%. And yet, these fools with a totally ineffective vaccine, still want to vaccinate those kids. And amazing, think about this. They reached a 75%... You know, so 75% of this country has already been infected, and they had zero deaths. I mean, you can't be clearer at how safe these children are. The only thing that Marx is going to do is put them at risk. That's the only thing that the CDC and our government is planning on doing right now

is putting our children in unnecessary risk and erasing their ability to help us get to herd immunity. Amazing. Right. And let's talk about natural immunity herd immunities. A couple words here. We're going to talk about Moderna's vaccine, but we understand seroprevalence. That's the amount of antibodies in the population. that have been basically generated by exposure to the infection.

We have serial conversion. That's when an individual becomes infected. They mount this antibody response, which it could be picked up on a test. So talking about the test for a second, there's a test called an anti-N test. This is an antibody test. So these antibody tests check to see if you've been ever infected. Those are different than the PCR or lateral flow test. Those tell if you're infected at the moment, at the time of the test.

So looking at those, this anti-N test looks for antibodies. This is the quote from this article, kind of just describing this. This is going to set up our next study here. It's very important. Anti-N tests look for antibodies that recognize a molecule inside the virus called the nucleocapsid, the N. These are only produced if you have caught COVID-19 previously and show natural immunity. These antibody tests are kind of like the gold standard.

Because we've talked about the PCR test before. The false positives are off the charts, especially when these cycle thresholds get really about 30 from when I'm understanding. So we look at this study now. This study looked at, this is a zero conversion study. They looked at Moderna's phase three vaccine efficacy trial data. And they looked at it like it was called a nested analysis. So within that data, there was a group of people they looked at who were all infected with SARS

COVID-2 during the blinding phase of the trial. So here's the title, anti-nucal capsid antibodies following SARS-CoV-2 infection in the blinded phase of the MRNA 1273, that's Moderna shot, COVID-19 vaccine efficacy clinical trial. And let's just jump to the results, and then we can explain this a little bit. So this is what they found, the results. We analyzed data from 1,789 participants that included 1,298 placebo recipients and 4,000, I'm sorry, 491 vaccine recipients with SARS-CoV-2 infection during the blinded phase through March of 2021.

Among participants with PCR-confirmed COVID-19 illness, serial conversion, to anti-N antibodies at a medium follow-up of 53 days post-diagnosis occurred in 21 out of 52, which is 40% of the MRNA-1273 vaccine recipients versus basically 93% of the placebo recipients. So what we're saying here with their findings, even though the vaccinated were infected, only 40% showed that N antibody, the other 60% didn't show it. They did not convert it. So it's suggesting they're not-

Let me jump in here, Jeffrey. Let me jump in here and just sort of take, I want my team to take this back to the definition of this anti-N antibody test because I think there's something we really need to get across. Listen to what it's saying. Anti-N tests look for antibodies that recognize a molecule inside the virus called the nucleocapsid. These are only produced if you have caught COVID-19 previously and show natural immunity. Remember the question we have had for the last two years is what happens if you get infected after the vaccine? are you then naturally immune the way a naturally immune person would be? What this is clearly showing us, Jeffrey, is they are not. They are not getting antibodies to this nucleocapsid. Only 40% of them are.

So they're not getting the full natural infection. Therefore, they don't have that full robust herd immunity that the naturally infected do. 90, was it? 95% of them are showing this nucleocapsid and only 40% of the vaccinated. So that's what this is showing us straight from Moderna's own data, right? Right, right, absolutely. And it is 93% of the placebo recipients are showing it. So, and as they document this, researchers, public health agencies, they say natural immunity from, you know, previous infection or vaccination. So they would lump up into the same ball and just throw it out there and say it's all good.

But this is this study is suggesting that the vaccinated are not producing a broad antibody response here because they're not producing these antibodies. And also the accuracy of these tests in producing this in people and the vaccine. vaccinated especially was an end point, an endpoint for these trials. So this is, listen to what these authors have to say here. They say COVID-19 vaccine efficacy trials use anti-end antibody, zero conversion as a secondary or exploratory endpoint to assess vaccine efficacy against symptomatic, I'm sorry, asymptomatic SARS-CoV-2 infection or as part of secondary endpoint to assess vaccine efficacy against SARS-CoV-2 infection of any severity. As we found that infection in a placebo arm are about twice as likely to manifest through anti-n antibody seroconversion as those in the

vaccine arm. Our results suggest that caution is needed when interpreting vaccine estimates against such endpoints. Well, too late, I guess, because 60% are not showing, basically that they're saying 60% during this trial are not showing they had asymptomatic infection or symptomatic infection or symptomatic infection. So we're going to say, look how good the vaccinated did as far as being infected compared to the unvaccinated. They had been infected, but it wasn't being detected by the test that they were using in the trials. Right.

We're talking. They were testing for the end, the Nucular caps are saying, well, they don't have it. So look, this vaccinated person didn't catch it either, only through PCR tests and looking at this closer to say, oh, no, there's a whole group. 60% of them were infected. You just didn't see it because you were using a test that was looking for the wrong thing amongst the vaccinated. That's, so we, so basically just burn any efficacy numbers that came out of these trials.

It's a disaster. It's suggesting that there were a lot of, a lot more breakthrough infections in these trials that we know because they were immunologically silent, essentially. And so we're flying blind now. They were flying blind in the trials. Let's look, let's finish this up and just look at one of the tables from the trial, just to show, give an idea here. So that top line going across is all of the data. from disease that's the days they had they they were found to have SARS cov to PDV that's the the patient visit that's when they are unblinded so five to

150 but if you look all the way to the right it breaks it down these are the vaccinated that we're not basically converting to this anti-n antibody so you have 40% was the total that's what we talked about but from the five to 53 days so the first basically the first 53 days only 32% 32.1% we're converting. So you're talking almost 68% in the first 353 days weren't converting to this. So if they have a PCR test, that's positive, and they go to do this kind of gold standard antibody test, the antibody test is going to show, no, we don't have anything here. So this must not be, you know, a COVID infection. This must be something else. We're not going to count that.

Absolutely incredible study. And, you know, we're going a little deeper on that in that science, but it's just so important to understand for possibly the future here, as we're seeing these these variants and these these cases rise.